...
首页> 外文期刊>Kidney international. >Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors
【24h】

Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors

机译:冠状动脉疾病,循环内皮祖细胞的危险因素以及HMG-CoA还原酶抑制剂的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Recent studies suggest that postnatal neovascularization relies not exclusively on sprouting of preexisting vessels ("angiogenesis"), but also involves the contribution of bone marrow–derived circulating endothelial progenitor cells (EPCs). EPCs can be isolated from peripheral blood or bone marrow mononuclear cells, CD34+ or CD133+ hematopoietic progenitors. Infusion of EPCs was shown to promote postnatal neovascularization of ischemic tissue after myocardial infarction in animal models and initial clinical trials. Moreover, circulating endothelial precursor cells can home to denuded arteries after balloon injury and contribute to endothelial regeneration, thereby limiting the development of restenosis. Thus, circulating endothelial cells may exert an important function as endogenous repair mechanism to maintain the integrity of the endothelial monolayer and to promote ischemia-induced neovascularization. However, risk factors for coronary artery disease, such as diabetes, hypercholesterolemia, and hypertension are associated with impaired number and function of EPC in patients with coronary artery disease. Therapeutically, the reduction of EPC number and the decreased functional activity in patients with coronary artery disease was counteracted by 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (statins), vascular endothelial growth factor (VEGF), estrogen, or exercise. At the molecular level, these factors are well established to activate the phosphatidyl-inositol-3-kinase (PI3K)-Akt-dependent activation of the endothelial nitric oxide synthase (eNOS), suggesting that the PI3K-Akt-eNOS signaling pathway may be involved in the transduction of atheroprotective factors. Taken together, the balance of atheroprotective and proatherosclerotic factors may influence EPC levels and their functional capacity to improve neovascularization and endothelial regeneration.
机译:冠状动脉疾病,循环内皮祖细胞和HMG-CoA还原酶抑制剂的作用的危险因素。最近的研究表明,产后新生血管形成不仅仅依赖于已有血管的萌芽(“血管生成”),而且还涉及骨髓来源的循环内皮祖细胞(EPC)的贡献。 EPC可以从外周血或骨髓单核细胞,CD34 +或CD133 +造血祖细胞中分离出来。在动物模型和初步临床试验中,灌注EPCs可促进心肌梗死后缺血组织的新生血管新生。而且,循环的内皮前体细胞可在球囊损伤后归巢于裸露的动脉并有助于内皮再生,从而限制了再狭窄的发展。因此,循环的内皮细胞可发挥重要的功能作为内源性修复机制,以维持内皮单层的完整性并促进局部缺血诱导的新血管形成。但是,冠心病的危险因素,例如糖尿病,高胆固醇血症和高血压,与冠心病患者的EPC数量和功能受损有关。在治疗上,冠心病患者的EPC数量减少和功能活性降低被3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类药物),血管内皮生长因子(VEGF),雌激素,或运动。在分子水平上,这些因素已被充分证实可以激活磷脂酰肌醇-3-激酶(PI3K)-Akt依赖性内皮一氧化氮合酶(eNOS)的激活,这表明PI3K-Akt-eNOS信号通路可能是参与动脉粥样硬化保护因子的转导。两者合计,动脉粥样硬化保护因子和动脉粥样硬化前体因子的平衡可能影响EPC水平及其改善新血管形成和内皮再生的功能能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号